SCHEMBL802329

SCHEMBL802329

Cc1ccccc1-c1cc(Nc2n[nH]c3ccccc23)c2c(n1)CCCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.38
FADS1 O60427 2/20 0.38
ADRA2A P08913 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
TRPA1 O75762 1/20 0.38
GRM4 Q14833 2/20 0.37
EGFR P00533 3/20 0.36
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ACP1 P24666 1/20 0.35
ACHE P22303 3/20 0.35
BCHE P06276 1/20 0.35
EPHA4 P54764 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802269 0.89 GSK3A (0.44) FADS1KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL802268 0.88 FADS1 (0.42) FADS1ADRA2ATRPA1GRM4EGFR
SCHEMBL12619795 0.86 ACP1 (0.42) FADS1ADRA2AALDH1A1TRPA1ACP1
SCHEMBL802350 0.82 EGFR (0.41) FADS1ADRA2AKDM4EALDH1A1CYP1A2
SCHEMBL802671 0.81 FADS1 (0.41) FADS1ADRA2AALDH1A1CYP1A2TRPA1
SCHEMBL13055190 0.79 FADS1 (0.36) FADS1ADRA2ATRPA1GRM4ACHE
SCHEMBL802334 0.78 FADS1 (0.45) FADS1EGFRACHEBCHEULK1
SCHEMBL802274 0.77 PIK3CA (0.42) FADS1ADRA2ATRPA1GRM4
SCHEMBL805536 0.77 ACP1 (0.44) FADS1TRPA1EGFRACP1ACHE
SCHEMBL802417 0.76 VCP (0.45) VCPFADS1ADRA2ATRPA1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 VCP 4775/4885FADS1 3442/4885ADRA2A 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.